Rein Therapeutics (RNTX) Competitors $1.16 -0.05 (-3.75%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock RNTX vs. COYA, ATOS, MGNX, ZURA, HURA, ANEB, ANIX, VIRI, TCRX, and AVTXShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Coya Therapeutics (COYA), Atossa Genetics (ATOS), MacroGenics (MGNX), Zura Bio (ZURA), TuHURA Biosciences (HURA), Anebulo Pharmaceuticals (ANEB), Anixa Biosciences (ANIX), Virios Therapeutics (VIRI), TScan Therapeutics (TCRX), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Coya Therapeutics Atossa Genetics MacroGenics Zura Bio TuHURA Biosciences Anebulo Pharmaceuticals Anixa Biosciences Virios Therapeutics TScan Therapeutics Avalo Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Does the media refer more to RNTX or COYA? In the previous week, Coya Therapeutics had 10 more articles in the media than Rein Therapeutics. MarketBeat recorded 13 mentions for Coya Therapeutics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.01 beat Coya Therapeutics' score of 0.09 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RNTX or COYA? Coya Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 190.49%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, RNTX or COYA? Coya Therapeutics has higher revenue and earnings than Rein Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.86-0.40Coya Therapeutics$3.55M26.77-$14.88M-$1.24-4.58 Is RNTX or COYA more profitable? Coya Therapeutics' return on equity of -61.05% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -86.07% -31.11% Coya Therapeutics N/A -61.05%-53.61% Do institutionals and insiders have more ownership in RNTX or COYA? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, RNTX or COYA? Rein Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. SummaryCoya Therapeutics beats Rein Therapeutics on 9 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.66M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.4020.4930.2925.74Price / SalesN/A356.37463.41115.83Price / Cash2.6843.0338.2159.48Price / Book2.698.608.826.15Net Income-$62.88M-$54.65M$3.25B$265.06M7 Day Performance4.05%5.86%3.70%2.60%1 Month Performance-17.50%8.86%5.84%2.83%1 Year PerformanceN/A13.33%29.92%25.58% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.16-3.8%N/AN/A$27.66MN/A-0.409News CoverageEarnings ReportCOYACoya Therapeutics1.8195 of 5 stars$6.08-0.3%$16.50+171.4%+18.0%$102.02M$3.55M-5.686News CoverageEarnings ReportAnalyst ForecastATOSAtossa Genetics2.7119 of 5 stars$0.79+1.9%$6.17+683.6%-37.1%$101.66MN/A-3.758Earnings ReportMGNXMacroGenics4.3512 of 5 stars$1.54-4.3%$5.40+250.6%-51.5%$101.57M$149.96M-1.73430Trending NewsEarnings ReportZURAZura Bio3.8392 of 5 stars$1.42-4.1%$14.33+909.4%-47.1%$101.19MN/A-2.033News CoveragePositive NewsEarnings ReportHURATuHURA Biosciences1.8902 of 5 stars$2.30-5.3%$12.67+450.7%N/A$100.46MN/A0.00N/ANews CoverageANEBAnebulo Pharmaceuticals2.2333 of 5 stars$2.41+0.4%$5.50+128.2%+26.8%$98.60MN/A-9.274Short Interest ↑ANIXAnixa Biosciences2.8683 of 5 stars$2.98-1.0%$9.00+202.0%-4.2%$96.96M$210K-7.845VIRIVirios Therapeutics0.1129 of 5 stars$4.890.0%$5.00+2.2%+2,635.0%$94.17MN/A-18.115Gap UpTCRXTScan Therapeutics3.6703 of 5 stars$1.64-0.6%$7.80+375.6%-67.9%$93.38M$2.82M-1.50100News CoverageEarnings ReportAnalyst ForecastAVTXAvalo Therapeutics3.2371 of 5 stars$8.93+6.9%$30.00+235.9%-6.6%$90.41M$440K0.0040Short Interest ↓ Related Companies and Tools Related Companies COYA Competitors ATOS Competitors MGNX Competitors ZURA Competitors HURA Competitors ANEB Competitors ANIX Competitors VIRI Competitors TCRX Competitors AVTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access